Kornimate/medical-research-clean huggingface dataset:
vitamin d supplementation for bipolar depression

Conditions: Bipolar Disorder; Bipolar Depression

Summary: the purpose of this study is to whether vitamin d supplementation in those with low levels may reduce depression symptoms in people experiencing bipolar depression.


Eligibility criteria:
inclusion criteria: * adults \>18years old * bipolar disorder (i,ii or nos), * madrs score\>7 (mild), * 25(oh)d level \<30ng/ml (insufficient). * able to take the prescribed vitamin d by mouth exclusion criteria: systemic diseases such as: * liver and kidney diseases, * known parathyroid disorder, * disorders of vitamin d metabolism, * taking vitamin d replacement therapy, * fat digestion disorder, * diabetes mellitus, * gi surgery * if the serum calcium in the range 2.50-2.55 mmol l, inclusion required a serum pth below 5.0 pmol l-acute psychiatric urgency: * active suicidality, * acute psychosis, * active substance use\<6mo or * pregnant or nursing females
a first-in-human, single-ascending-dose study of ibi3002 in healthy participants and mild to moderate asthmatics

Conditions: Healthy Participants; Asthma

Summary: this is a single-center, randomized, double-blind, placebo-controlled, phase 1, single-ascending-dose study to evaluate the safety, tolerability, pharmacokinetics (pk) and pharmacodynamics (pd) of ibi3002 in healthy participants and mild to moderate asthmatics. subjects will be randomly assigned to different dosages of ibi3002 and matched placebo groups. the entire trial cycle includes a 4-week screening period, 1-day treatment period and 5-week follow-up period.


Eligibility criteria:
inclusion criteria: 1. participants must sign an institutional review board (irb) approved informed consent form before any study specific procedures. 2. participants must be between 18 and 55 years old, inclusive. 3. participants must have a body mass index (bmi) between 18 to 32 kg/m2, inclusive. 4. participants of childbearing potential and their partners should use highly effective methods of birth control during the study and until 6 months after the study. 5. participants with asthma must have: * documented physician diagnosis of asthma for at least 12 months prior to screening and confirmed by the investigator; * elevated feno defined as ≥ 25ppb; * documented and stable gina 2023 recommended step 1\~3 controller treatment (defined as ≤ 250μg fluticasone propionate dry powder formulation equivalent total daily dose of ics, alone or in combination with laba) for the last 3 months prior to screening; * pre-bd fev1 ≥ 60% of prediction and post-bd fev1/forced vital capacity (fvc) \> 70%. exclusion criteria: 1. history of allergies to any components of ibi3002 or placebo. 2. history of blood or needle sickness, or those who cannot tolerate venipuncture. 3. female participants who are pregnant or breastfeeding at screening or randomization. 4. history of participating in a clinical trial within 1 month or 5 half-lives of the test drug (whichever is longer) prior to randomization, or those who are currently participating in a clinical trial. 5. history of severe infection or significant injury within 6 months, or surgery within 3 months, or any infection requiring systemic medication within 1 month prior to screening or randomization. 6. history of live or attenuated vaccination within 1 month prior to randomization, or those who plan to be vaccinated during the study. 7. for asthmatics only: history of a life-threatening asthma attack that required mechanical ventilation and/or was associated with hypercapnia, respiratory arrest or hypoxic seizures within the last 5 years prior to randomization. 8. for asthmatics only: history of asthma worsen or exacerbation resulting in emergency room (er) visits or overnight hospitalizations, or an increase in asthma maintenance therapy, or use of systemic glucocorticoids within the last 3 months prior to randomization.
trends over time (1990-2010) of diarrhoea-related incidence, hospitalizations and deaths in children of panama

Conditions: Gastroenteritis

Summary: this study aims at collecting data from secondary sources to obtain baseline incidence and monitor trends over time (1990 - 2010) of reported gastroenteritis cases, gastroenteritis related hospital discharges and gastroenteritis related deaths in children \< 5 years of age in panama before and after implementation of rotarix™ universal mass vaccination.

data will be collected from systematic review of the databases of epidemiologic surveillance system, hospital discharges and deaths for all cause gastroenteritis related outcomes.

Eligibility criteria:
inclusion criteria: * diarrhea cases, diarrhea associated hospital discharges, and diarrhea related deaths occurring in children \<5 years of age during the period analyzed and registered in the epidemiologic surveillance system of the ministry of health, in the mortality database of the contraloría general de la república and in the hospital discharge records of the selected hospitals, will be collected for the study. exclusion criteria: * not applicable
efficacy and neural correlates of personalized treatment with transdermal nicotine replacement

Conditions: Tobacco Use Disorder; Nicotine Dependence

Summary: this study involves the use of personalized nicotine patch dosing as a treatment strategy for smokers who cannot quit smoking after 2 weeks of using the standard nicotine patch dose. functional magnetic resonance imaging scans will also be obtained from all study participants before and after treatment. the first aim of the study is to determine if the treatment method under investigation is safe and more effective at increasing quit rates in smokers who do not respond to standard therapy.the second aim is to determine if there are any treatment- or cessation-related changes in brain function.

nicotine replacement therapy (nrt) is limited in efficacy. one possible explanation for this limited efficacy is that the nicotine dose received in standard therapy is not enough to replace the amount of nicotine that smokers typically receive from their cigarettes. in an effort to counteract this problem, this study will increase the nicotine patch dose of smokers until they no longer feel the need to keep smoking or they cannot tolerate a higher nicotine dose. smokers who cannot quit using 21 mg nicotine patch for 2 weeks will be randomized to either the experimental arm of the study where nicotine patch doses will be adjusted according to individual need or the positive control arm where standard nrt smoking cessation therapy will be employed. the primary outcome measure will be continuous abstinence during the last 4 weeks of treatment. in addition, participants will be assessed to see how treatment has impacted their resting state neural activity as well as their responsiveness to smoking and emotional cues. follow up sessions will be used to assess long term abstinence as well as long term change in neural activation.

Eligibility criteria:
inclusion criteria: * daily tobacco smoker of * aged 19 to 65 years old * intending to quit smoking within the next 30 days * interested in using transdermal nicotine replacement therapy (nicotine patch) exclusion criteria: * at least weekly use of tobacco products other than cigarettes * breast feeding, pregnancy or not using a reliable form of birth control * any generalized skin disorders precluding the use of the patch * immediate post-myocardial infarction period or life-threatening arrhythmias, severe or worsening angina pectoris or recent cerebral vascular accident * any clinically significant electrocardiogram (ecg) abnormalities * currently using nrt or other smoking cessation pharmacotherapy * any known hypersensitivity or allergies to any of the components comprising the nicotine patch * mri contraindications (e.g., metal in body, claustrophobia) as per the camh ric screening questionnaire * diagnosis of terminal illness.

Keywords: nicotine patch nicotine mouth spray smoking cessation quit smoking abstinence dependence nicotine tobacco transdermal nicotine replacement therapy functional magnetic resonance imaging neuroimaging cue reactivity resting state bold fmri
development and feasibility testing of a mobile phone-based hiv primary care engagement intervention

Conditions: HIV; Adherence

Summary: this is an open-trial pilot study in which adult methadone maintenance treatment patients who are living with hiv but are not engaged in hiv primary care (i.e., missed appointments, non-adherence to medication) will be recruited to participate in a hiv primary care engagement study. the purpose of this study is to develop and test the feasibility and acceptability of a mobile phone-based health (mhealth) text messaging intervention to improve engagement in hiv primary care among substance abusing populations with hiv.


Eligibility criteria:
inclusion criteria: * client of a methadone maintenance treatment program * hiv positive (status confirmed by medical records) * at least 18 years of age * english speaking * comfortable using a mobile phone (to send and receive text messages) * lives in new york city * willingness to attend at least two design sessions * willingness to attend one usability testing session, and participate in a post-usability survey and exit interview.

Keywords: engagement in care mhealth
relevance - rwe study in unresectable non-small cell lung cancer (stage iii) in canada

Conditions: Non-small Cell Lung Cancer

Summary: in the relevance study, we will develop a scalable electronic medical report data capture platform to collect and analyse real-world data in the stage iii nsclc population in canada across several canadian cancer centres. subsequent analyses will examine treatment patterns and clinical outcomes, including overall survival, for these patients, stratified by durvalumab regimen or non-durvalumab regimen during the time of the pacific patient support program.


Eligibility criteria:
inclusion criteria: * male or female aged 18 years or older * patients must have histologically or cytologically documented diagnosis of nsclc with a locally advanced, or locally recurrent (stage iii) disease between november 1, 2017 and december 31, 2019 at the centre (note: durvalumab uptake rate requires a secondary index date, such as initiation of crt before availability of durvalumab in may 2018) exclusion criteria: * patients treated with durvalumab in clinical studies prior to the start date * clinical trial patients where treatments received are blinded in the patient medical records

Keywords: real-world evidence, treatment patterns, clinical outcomes, durvalumab, chemoradiotherapy
effect of music on pain and anxiety in chronic pain patients undergoing lumbar interventional procedures.

Conditions: Chronic Pain; Anxiety

Summary: the purpose of this study is to evaluate, subjectively and objectively, whether playing music during procedures for treatment of chronic lower back pain has an effect on patients' anxiety and pain. the investigators hypothesize that playing music will result in reduced patient reported anxiety and pain scores and less variation from baseline of vital signs versus patients in the control group without music therapy. this is a pilot study.


Eligibility criteria:
inclusion criteria: 1. age greater than or equal to 18 2. female or male 3. patients undergoing standard of care lumbar spinal interventional procedures including: epidural steroid injections, facet injections, medial branch blocks exclusion criteria: 1. patients who cannot consent for themselves, including cognitively impaired patients. 2. non-english speaking patients 3. patients taking beta blocker medication 4. patients that have a pacer and have a set rate 5. patients with self-reported hearing problems or with hearing aids
self-management education and support to promote psychosocial health among stroke survivors and informal caregivers in a virtual stroke community (support)

Conditions: Stroke

Summary: the purpose of this study is to create a virtual stroke community for stroke survivors and informal caregivers of stroke survivors by customizing an existing ve intervention to incorporate real-time, stroke-specific, psychosocial self management education (sme) and social interactions, to test feasibility, acceptability, and usability of the customized intervention for stroke survivors and informal caregivers of stroke survivors and to obtain and explore data to derive evidence-based hypotheses and properly design and conduct a future, larger trial to demonstrate treatment efficacy.


Eligibility criteria:
inclusion criteria: * stroke survivors that have experienced an ischemic or hemorrhagic stroke event and their caregivers * can read, write, and speak english * are able to provide written consent * are computer literate (have used a computer for ≥1 month) * have access to a computer with broadband internet at home * understand how to use the internet (accessed the internet on ≥2 occasions) exclusion criteria: * reside outside of the home * montreal cognitive assessment score of \<9 indicating moderate to severe impairment * caregivers that provide long-distance care. i

Keywords: depression anxiety
comparison of efficacy of oral fluconazole versus oral itraconazole in the treatment of pityriasis versicolor

Conditions: Pityriasis Versicolor

Summary: this study compares the efficacy of two drugs, namely flucanazole and itraconazole for the treatment of a common fungal infection of skin.

pityriasis versicolor is a common fungal infection of the superficial skin layers. avalible treatment options include topical and systemic drugs. fluconazole and itraconazole are commonly used systemic agents. the aim of this study is to compare the efficacy of the two systemic drugs.

Eligibility criteria:
inclusion criteria: * all cases of pityriasis versicolor exclusion criteria: * patients with history of chronic renal or liver disease, malignancy , or undergoing any kind of chemotherapy or radiotherapy or having cardiac conduction abnormalities. * patients who received any anti-fungal therapy in the last one month. * pregnant or lactating women.

Keywords: pityriasis versicolor fluconazole itraconazole
oral immunonutrition with synbiotics, omega 3 and vitamin d in patients undergoing duodenopancreatectomy for tumoral lesion.

Conditions: Pancreatic Cancer; Complication,Postoperative; Surgery

Summary: the purpose of this trial is to demonstrate that synbioimmunonutrition (si) combined with omega-3 fatty acids (o3) and vitamin d (d) is superior to conventional 7-day preoperative immunonutrition in terms of reducing overall morbidity, in cases of duodenopancreatectomy for tumoral lesion.

to the best knowledge of the investigators, a comprehensive multimodal approach to reduce postoperative morbidity in duodenopancreatectomies has not yet been evaluated. in the study, the investigators combine the main nutritional interventions currently available and already having an individual scientific basis, sequentially and simultaneously, for a potential synergistic effect. in cases of duodenopancreatectomy for tumoral lesion, a group of patients taking only conventional immunonutrition regimen (cir), for 7 preoperative days, will be compared with a second group where immunonutrition will be maximised by the addition of omega 3 for 1 week prior to the administration of cir, synbiotics for 14 days pre- and post-operatively, and preoperative vitamin d supplementation for 6 days, in terms of postoperative overall morbidity.

Eligibility criteria:
inclusion criteria: * all cases of duodenopancreatectomy for tumoral lesions. exclusion criteria: * distal or total pancreatectomies, as well as procedures for chronic pancreatitis * patient refusal or inability to provide informed consent * use of dietary supplements containing omega 3, pre- or probiotics within 15 days prior to protocol initiation * severe cardiorespiratory or renal insufficiency * hiv * cirrhosis child-pugh b-c * inability to feed by mouth * intestinal obstruction * unresectable tumor or metastatic disease on preoperative work-up * cardiac valvular pathology * short bowell syndrome * haemophilia * known allergy or intolerance to fish oil, fish or shellfish, milk, soy or components of the products used * bmi \< 16kg/m2 * weight loss \> 15% in the last 6 months * little or no food in the last 10 days * hypercalcemia * pregnancy, breastfeeding

Keywords: synbiotics omega 3 vitamin d probiotics prebiotics
smoking relapse prevention among copd ex-smokers

Conditions: Chronic Obstructive Pulmonary Disease; Smoking Cessation

Summary: a placebo-controlled trial to determine whether recent ex-smokers with copd who successfully stop smoking after taking varenicline are less likely to relapse back to smoking if they continue using varenicline for a further 12 weeks

smoking remains the leading cause of chronic obstructive pulmonary disease (copd), a leading cause of death and disability in new zealand. copd particularly affects indigenous māori and pacific people, given their higher rates of smoking. copd patients tend to have a higher level of nicotine dependence and, as a result, often find quitting harder and are more likely to relapse back to smoking. a clinical trial (n=262) is planned in auckland, new zealand to determine whether extended varenicline treatment combined with behavioural support can prevent relapse back to smoking in recent ex-smokers with copd. smoking cessation and relapse prevention are the most cost-effective interventions available for copd patients that smoke, irrespective of their disease stage. the trial has the potential to significantly improve the outcomes of this common and chronic health condition in new zealand.

Eligibility criteria:
inclusion criteria: * daily smokers * diagnosed with copd (as per the global initiative for chronic obstructive lung disease \[gold\] criteria, namely: a characteristic clinical picture of dyspnea, cough or sputum, with a history of exposure to risk factors, plus a post-bronchodilator forced expiratory volume in one second / forced vital capacity fev1/fvc ratio of \<0.70) * have stable copd (i.e. no exacerbation, hospital admission, or use of antibiotics or prednisone in the past six weeks) * can provide consent * reside in the auckland region of new zealand * eligible under new zealand special authority to receive subsidised varenicline * prepared to make a quit attempt with varenicline * have access to a phone exclusion criteria: * a history of definite asthma and/or atopy * contraindications to varenicline * used varenicline in the past 12 months * a history of serious psychiatric illness or significant cognitive impairment * major or uncontrolled co-morbidities (such as uncontrolled heart failure, infection or rapidly progressive condition) * a life expectancy of \< 12 months * are currently using another cessation medication (including e-cigarettes)
non-invasive vagal stimulation for frequent premature ventricular complexes

Conditions: Premature Ventricular Contraction

Summary: a prospective sham-controlled randomized clinical trial to assess the effect of low-level tragus stimulation (llts) in patients with frequent premature ventricular complexes (pvcs)

this is a two-center, prospective, cross-over, sham-controlled, double-blinded, randomized clinical trial. all the patients will receive a cardiac event monitor at baseline for 28 days, the patient will switch the epatch after 14 days . patients will be allocated to either llts first and then sham-stimulation, or sham-stimulation first and then llts. each treatment period (sham-stimulation and llts) will last 10 days. the parasym device will be used, and the patients will receive llts or sham-stimulation for 1 hour daily. the wash-out period between the two treatments will last 8 days. patients will be continually monitored via event monitor for 28 days in duration.

Eligibility criteria:
inclusion criteria: * adults (\>18 years old) but \< 80 years of age * symptomatic pvcs or asymptomatic pvcs with a burden \> 5% * intolerant to or unwilling to take beta blockers and nondihydropyridine calcium channel blockers or beta blockers and nondihydropyridine calcium channel blockers have proved ineffective exclusion criteria: * ischemic cardiomyopathy with lvef \< 40% * severe heart failure (new york heart association class iii, or iv) or valve disease * sustained ventricular tachycardia * structural heart disease or myocardial scar * pregnancy or nursing * patients with known thyroid issues, on renal dialysis. * patients with prolonged first-degree block, high degree av block (2nd or 3rd degree), bivascular block and documented sick sinus syndrome * hypotension due to autonomic dysfunction * patients with cardiac implantable electronic device (icd or ppm) , hearing aid implants or any implanted metallic or electronic device * patients who have had prior cervical vagotomy * patients with skin on the tragus that is broken or cracked * patients with a history of baseline cardiac disease or atherosclerotic cardiovascular disease, including congestive heart failure (chf), known severe coronary artery disease or recent myocardial infarction (within 5 years) and patients diagnosed with narrowing of the arteries (carotid atherosclerosis)
use of continuous glucose monitoring in non-diabetic population to compliment signos mobile health platform

Conditions: Weight Loss; Metabolic Syndrome; Pre-diabetes; Central Obesity; Glucose Intolerance; Metabolic Glucose Disorders

Summary: metabolic syndrome and resulting downstream health effects remains a growing health concern. in published trials, the use of continuous glucose monitoring (cgm) assists behavioral changes efforts, leading to improved adherence and results from diet and exercise changes in individuals with obesity, pre-diabetes and diabetes. mobile health (mhealth) platforms provide satisfactory, easy-to-use tools that help participants in the pursuit of weight change goals. we hypothesize that the use of cgm data and targeted coaching and nutrition education will assist with weight optimization goals in the general (non-diabetic) population using the signos mhealth platform, with associated health benefits.

the scope of this study is to enroll existing and new signos users in a volunteer study that utilizes a continuous glucose monitor (cgm) and mobile health application \[signos\] to optimize general wellness and body weight and composition. this is a no more than minimal risk study.

Eligibility criteria:
inclusion criteria: * 18 years and above * own a smartphone and be willing to install the signos app to use the app, receive messages or notifications, and input weight and other data. * willingness to complete questionaries or other surveys * able to speak and read english exclusion criteria: * medical diagnosis of type 1 diabetes * medical diagnosis of type 2 diabetes * current medical diagnosis of an eating disorder (anorexia or bulimia) or previously struggled with disordered eating behaviors with current bmi less than 24 * medical conditions (e.g., such as seizure disorder) requiring a specific medical diet. * inborn errors of metabolism such as phenylketonuria (pku), glycogen storage disease, fructose intolerance, maple sugar urine disease (msud). * chronic or severe disease (e.g, chronic obstructive pulmonary disease \[copd\], coronary artery disease, cerebrovascular accident \[cva\], or cardiac arrhythmia) that would preclude a subject from safely participating in dietary recommendations and/or physical activity * history of gastric bypass or other bariatric surgery * history of 10 or more soft tissue skin infections (such as cellulitis or abscesses) * intolerable skin reaction from adhesive * currently taking any of the following medications: hydroxyurea, insulin, sulfonylureas, or medications prescribed specifically for the treatment of diagnosed diabetes * vulnerable populations such as minors, prisoners, or pregnant women will not be enrolled in this study. women who become pregnant will be excluded at that time. * inability or unwillingness of subject to give informed consent

Keywords: health and wellness excess adiposity